FDA extends review of Exelixis' colorectal cancer drug candidate

RegulatoryNeutral

AI Analysis

Summary

Exelixis submitted new safety and efficacy data for its metastatic colorectal cancer drug candidate, resulting in a three-month extension of the FDA review timeline.

Outcome Details

FDA review extended by three months due to submission of new safety and efficacy data

Importance:5/10

Sentiment:

0.00

FDAcolorectal cancermCRCregulatoryreview extension

Related Companies

$EXEL

Read the original article

Published by Endpoints News on September 11, 2026 4:02 PM

Read Original